Despite tremendous progress in basic science, there have been few breakthroughs in the treatment of many CNS diseases. CNS quantitative systems pharmacology is based on the realization that human pathology is driven by a network imbalance rather than deficits at a single target or gene.
Computer-based modeling of biophysically realistic neuronal network circuits calibrated with human imaging and clinical data is a translational tool to assess the outcome of therapeutic interventions in complex brain circuits. The company provides insights into the systemic behavior at each R&D stage in high impact decision processes.
We provide model based decision support and knowledge support from target validation to personalized medicine for:
Our modeling addresses the following key questions:
We offer computer simulation support in drug development, based on the affinity and pharmacology of a new drug towards human receptors for Alzheimer's disease, schizophrenia and Parkinson's disease.
Validating the impact of targets in the combined neuronal circuit outcome
Candidate selection in multi-target medicinal chemistry campaign
Off-target pharmacological activity of candidate compounds
Early assessment of human metabolite effects of candidate compounds
Synergistic effects of off-target pharmacological activity of candidate compounds
Early Clinical Development
Prediction of functional biomarkers (pharmaco-fMRI, pharmaco-EEG)
Optimal dosage and dosage schedule
Late Clinical Development
Simulations of comedication effects on primary pharmacology
Effect of genotype randomization
Virtual patient trial based on pharmacokinetic and mechanistic pharmacodynamic simulation
Chronopharmacology, i.e. optimal dosing time given the circadian rhythm of specific brain circuits
Simulation of different switching schedules
Understanding the biology behind pharmacogenomics analysis of responders
Optimization of clinical head-to-head trials
Simulations of the drug in real-life conditions (i.e. polypharmacy)
In Silico Biosciences, Inc. has not received any reviews.
In Silico Biosciences, Inc. has not received any endorsements.